Keenova
Highly Engaged Employees
Manufacturing · Ireland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
College Business & Technology Park Cruis...Phone Number
+353 16960000Website
www.keenova.comRevenue
$540.1 MillionIndustry
About Keenova
Keenova Org Chart
Executive Director
Global Senior Director, Regulatory Labeling
Senior Director, Program Management
Senior Director, Clinical R & D
Senior Director, Manufacturing Operations (Bi...
Global Senior Director, Quality & Compliance
Senior Director, Administrative Assistanct Fo...
Dea Affairs Director, Security Operations
Director, Operations
Is Keenova your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Keenova is spiking on competitors!
Funding: Get notified immidiatlly once Keenova has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Keenova launches new products
Keenova, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Keenova has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if Keenova had a recent Job posting/layoffs
Earning: See what the market has to say on Keenova recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Keenova
Recommended Actions
Reach out to Masked Content who joined Keenova as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Keenova is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Keenova is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Keenova.
Keenova Tech Stack
A closer look at the technologies used by Keenova
Most Recent Scoops
Keenova News & Media
Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe
First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe Hammer toe treatment today is limited to mainly orthotics,...Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie's disease treated with XIAFLEX® (collagenase clostridium histolyticum). The...Keenova Therapeutics to Report Second Quarter 2026 Financial Results on August 11, 2026
DUBLIN, July 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc, a leading developer and manufacturer of branded therapeutics, announced today that it will report its second quarter 2026 financial results on Tuesday, August 11, 2026, before market open. The Company will host a conference...Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research
DUBLIN, July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. Sponsored by Keenova, the retrospective, physician-reported,...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Keenova
Based in Dublin, Ireland, Keenova (formerly Mallinckrodt Pharmaceuticals) is a therapeutics company focused on targeted, specialty treatments. It addresses gaps in patient care by delivering science-based medicines and working with payors and providers to ensure patients access the therapies they need.... Read More